SavedAdd your journal

Journals / Kocatepe Tıp Dergisi / 2021 / Cilt: 22 - Sayı: 2

DOES PRETREATMENT NEUTROPHIL‑LYMPHOCYTE RATIO AND PLATELET-LYMPHOCYTE RATIO HAVE A THERAPEUTIC EFFECTS IN RECURRENT AND/OR METASTATIC GYNECOLOGICAL MALIGNANCIES?

REKÜRRENTVE/VEYA METASTATIK JINEKOLOJIK TÜMÖRLERDE TEDAVİ ÖNCESİ NÖTROFİL-LENFOSİT ORANI VE TROMBOSİT-LENFOSİT ORANI TERAPÖTİK ETKİYE SAHİP MİDİR?

Ozlem Yetmen DOGAN
Makbule EREN
Pages
125–131
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survival rates were 2 and 3 years 78% , 57% .

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: In this study, the effect of pre-treatment neutrophil-to lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) on gynecological malignancies that applied radiotherapy and /or radiochemotherapy was investigated.MATERIAL AND METHODS: The data obtained from 82 patients who applied to our clinic between 2009- 2014 and developed recurrence and/or metastasis during their routine follow-up were retrospectively evaluated.
📊
Key Findings & Data:Pre-treatment whole blood parameters of all patients were examined, and their effects on survival were analyzed by Kaplan Meier and the ROC curve.RESULTS: The median age was 57.5 (30-82), follow-up was 26 months.
💡
Conclusion & Impact:Overall survival rates were 2 and 3 years 78% , 57% .
🔬Design:Research Article
📍Scope:2009- 2014 Verileri
⚙️Variables:Radyoterapi · Jinekolojik kanserler · Nötrojil lenfosit oranı

Abstract

OBJECTIVE: In this study, the effect of pre-treatment neutrophil-to lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) on gynecological malignancies that applied radiotherapy and /or radiochemotherapy was investigated.MATERIAL AND METHODS: The data obtained from 82 patients who applied to our clinic between 2009- 2014 and developed recurrence and/or metastasis during their routine follow-up were retrospectively evaluated. Pre-treatment whole blood parameters of all patients were examined, and their effects on survival were analyzed by Kaplan Meier and the ROC curve.RESULTS: The median age was 57.5 (30-82), follow-up was 26 months. According to the blood values median WBC: 7.34, RBC: 4.33, hb: 11.7, hct: 36.4, MCV: 85.8, MCH: 27.6, MCHC: 32.1, plt: 270050, lymphocyte: 1,66, neutrophils: 4.79, monocytes: 0.56, eosinophils: 0.11, basophils: 0.1.Statistically; according to the ROC analysis, the boundary PLR value was 174 and the NLR value was 2.06. Overall survival rates were 2 and 3 years 78% , 57% . In univariate analysis the pre-treatment blood values; WBC > 7.34 (p = 0.01), the platelet value > 270050 (p = 0.021) and the absolute neutrophil value > 4.79 (p = 0.04) found to have a negative effect on survival. At the end of the ROC analysis, the NLR ratio was found to be above 2.06, adversely affecting survival (p = 0.005), but the PLR rate did not affect survival.CONCLUSIONS: In the future, the treatment method of patients diagnosed with gynecological cancer can be determined with a very simple and inexpensive blood test. High NLR before treatment can be used as a parameter indicating a more aggressive treatment approach may be required in patients.

Özet

AMAÇ: Bu çalışmada radyoterapive/veya radyokemoterapi uygulanan jinekolojik malignitelerde tedavi öncesi nötrofil-lenfosit (NLR) ve trombosit-lenfosit (PLR) oranlarının sağkalım üzerine etkisi incelenmiştir.dıkları ve yan etkilerini incelemek amacıyla planlanmıştır.GEREÇ VE YÖNTEM: 2009 - 2014 yılları arasında kliniğimize tüm tedavileri yapılmış ve rutin takipleri sırasında nüks ve/veya metastaz gelişmiş 82 hasta retrospektif olarak incelenmiştir. Tüm hastaların tedavi öncesi tam kan parametreleri incelenip, sağkalım üzerindeki etkileri Kaplan Meier ve ROC eğrisi ile analiz edildi.BULGULAR: Hastaların ortanca yaşı 57,5 (30-82) ve ortanca takip süresi 26 aydı. Kan değerlerine göre medyan WBC: 7.34, RBC: 4.33, hb: 11.7, hct: 36.4, MCV: 85.8, MCH: 27.6, MCHC: 32.1, plt: 270050, lenfosit: 1,66, nötrofil: 4.79, monosit: 0.56, eozinofiller: 0.11, bazofiller: 0.1. idi. ROC analizine göre, istatistiksel olarak PLR değeri 174 ve NLR değeri 2.06 idi. Genel sağkalım oranları 2 ve 3 yılda % 78 ve % 57 idi. Tek değişkenli analizde tedavi öncesi kan tablosunda WBC > 7.34 (p = 0.01), trombosit sayısı> 270050 (p = 0.021) ve mutlak nötrofil sayısı> 4.79 (p = 0.04) olması sağkalım üzerine olumsuz etkisi görüldü. ROC analizinin sonucunda bulunan, NLR oranının>2.06 sağkalımı olumsuz etkilediği (p = 0.005) ancak PLR oranı sağkalımı etkilemediği tespit edildi.SONUÇ: Gelecekte, jinekolojik kanser teşhisi alan hastaların çok basit ve ucuz bir kan testi ile tedavi şekli belirlenebilir. Yüksek NLR, hastalara daha agresif bir tedavi yapılması gerektiğini gösteren bir parametre olarak kullanılabilir.

🔖

Cite This Article

DOGAN, O. Y., EREN, M. (2021). DOES PRETREATMENT NEUTROPHIL‑LYMPHOCYTE RATIO AND PLATELET-LYMPHOCYTE RATIO HAVE A THERAPEUTIC EFFECTS IN RECURRENT AND/OR METASTATIC GYNECOLOGICAL MALIGNANCIES?. Kocatepe Tıp Dergisi, Cilt: 22 - Sayı: 2, 125–131. https://ajindex.com/articles/165375

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63(1):11–30. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in the critically ill. BratislLekListy 200; 102(1):5–14.
  2. Walsh SR, Cook EJ, Goulder F,Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer J Surg Oncol 2005; 91(3):181–184.
  3. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250(1):141–151.
  4. Bhatti I, Peacock O, Lloyd G,Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of Prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200(2):197–203.
  5. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lympocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J ThoracCardiovasc Surg 2009;137(2):425–28.
  6. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One 2014;9(3):e92079.
  7. Cho HB, Hur HW, Kim SW, et al.Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer ImmunolImmunother 2009;58(1):15–23.
  8. Lee Y-Y, Choi CH, Kim HJ, et al. Pretreatment Neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res 2012; 32(4):1555–1562.
  9. Zhang Y, Wang L, Liu Y, et al. Preoperative neutrophillymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. Int J Gynecol Cancer 2014;24(7):1319–25.
  10. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457- 65. Balkwill F and Mantovani A. Inflammation, cancer: back to Virchow?. Lancet 2001; 357: 539-45.
  11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140: 883-99.
  12. Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986;102: 1217-1223.
  13. Dubernard V, Arbeille BB, Lemesle MB, Legrand C. Evidence for an alpha granular pool of the cytoskeletal protein alpha actinin in human platelets that redistributes with th